SNTI$0.1772-5.74%
Senti Biosciences Holdings, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$5.52M
Float & O/S:
Inst Own:
DilutionScan read 33 of Senti Biosciences Holdings, Inc.'s SEC filings and found 3 warrant series, 4 convertibles, 1 ATM program, 1 equity line, 3 shelf registrations and 1 completed offering on file for SNTI. The latest dilution event on file is an offering on Oct 21, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
SNTI
Going-concern warning, merger closed, core business gone
- Business
- WeakGoing-concern doubt, $61.4M net loss, $6.5M cash
- Stock risk
- HighMerger completed, share count +4792% YoY, 216% dilution
Snapshot
Senti Biosciences is a clinical-stage biotech that just completed a merger giving away its main drug program for contingent payments, not cash. FY 2025 revenue was essentially zero ($22K) against a $61.4M net loss and $43.4M burned from operations.
What's Happening Right Now
- : After stockholders approved it on October 15, 2026, Senti Biosciences completed its merger with a Celadon Partners-controlled entity on October 21, 2026; the SENTI-202 program moves to the acquirer while Senti keeps its listing and Rett Syndrome/TIL programs, public holders get non-tradeable contingent value rights worth up to $60 million, the company sold shares to a Celadon affiliate for ~$2.5 million, and $16 million of convertible notes must be exchanged by October 28, 2026.
- : Conversion price $0.6261 → $0.3420.
- : Conversion price $0.6261 → $0.3420.
- : Conversion price $0.6261 → $0.3420.
- : Director Brenda Cooperstone resigned from the board and as Compensation Committee chair effective September 23, 2026, with no successor named.
- : Celadon Partners affiliates raised disclosed beneficial ownership to 54.6% of shares and committed another $2.5 million to buy newly issued stock tied to the merger closing.
- : Senti received Nasdaq deficiency notices on August 27, 2026 for trading below $1.00 for 30 days and for a stockholders' equity deficit, with until February 23, 2027 to regain compliance.
- : The Q2 2026 10-Q disclosed explicit going-concern doubt, with $6.5 million in cash, a $12.75 million quarterly net loss, and warnings the company might not sustain operations starting as early as Q4 2026.
